The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
Open accessAbstract
Purpose: We determined the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLT) of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when infused on days 1, 8, and 15 of a 28-day cycle in advanced solid tumor patients. We also characterized the pharmacokinetics of 17-AAG, its effect on chaperone and client proteins, and whether cytochrome P450 (CYP) 3A5 and NAD(P)H:quinone oxidoreductase 1 (NQO1) polymorphisms affected 17-AAG disposition or toxicity. Patients and Methods: An accelerated titration design was used. Biomarkers were measured in peripheral-blood mononuclear cells (PBMCs) at baseline and on days 1 and 15, and pharmacokinetic analysis was performed on day 1 of cycle 1. CYP3A5*3 and NQO1*2 genotypes were determined and correlated with pharmacokinetics and toxicity. Results: Twenty-one patients received 52 courses at 11 dose levels. DLTs at 431 mg/m 2 were grade 3 bilirubin (n = 1), AST (n = 1), anemia (n = 1), nausea (n = 1), vomiting (n = 1), and myalgias (n = 1). No tumor responses were seen. 17-AAG consistently increased heat shock protein (Hsp) 70 levels in PBMCs. At the MTD, the clearance and half-life (t 1/2) of 17-AAG were 11.6 L/h/m 2 and 4.15 hours, respectively; whereas the active metabolite 17-aminogeldanamycin had a t 1/2 of 7.63 hours. The CYP3A5*3 and NQO1*2 polymorphisms were not associated with 17-AAG toxicity. The CYP3A5*3 polymorphism was associated with higher 17-AAG clearance. Conclusion: The MTD of weekly 17-AAG is 308 mg/m 2. 17-AAG induced Hsp70 in PBMCs, indicating that Hsp90 has been affected. Further evaluation of 17-AAG is ongoing using a twice-weekly regimen, and this schedule of 17-AAG is being tested in combination with chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sain, N., Krishnan, B., Ormerod, M. G., Rienzo, A. D., Liu, W. M., Kaye, S. B., Workman, P., & Jackman, A. L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0445 · Cited by 92
RetractedMolecular Chaperones in the Cytosol: from Nascent Chain to Folded Protein
Hartl, F. U., & Hayer-Hartl, M. (2002) · Science · doi:10.1126/science.1068408 · Cited by 3,347
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones*
Pratt, W. B., & Toft, D. O. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.3.0303 · Cited by 1,791
Self-citationWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387
Young, J. C., Moarefi, I., & Hartl, F. U. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200104079 · Cited by 822
ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo
Panaretou, B., Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4829 · Cited by 735
Hsp90 inhibitors as novel cancer chemotherapeutic agents
Neckers, L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02316-x · Cited by 677
The genetic determinants of the CYP3A5 polymorphism
Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y.-Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00005 · Cited by 673
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639
Basso, A. D., Solit, D. B., Chiosis, G., Giri, B., Tsichlis, P., & Rosen, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206322200 · Cited by 628
In Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis
Obermann, W. M. J., Sondermann, H., Russo, A. A., Pavletich, N. P., & Hartl, F. U. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.4.901 · Cited by 601
Hsp90: Chaperoning signal transduction
Richter, K., & Buchner, J. (2001) · Journal of Cellular Physiology · doi:10.1002/jcp.1131 · Cited by 570
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent
Supko, J. G., Hickman, R. L., Grever, M. R., & Malspeis, L. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689048 · Cited by 510
Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.612 · Cited by 488
Schulte, T. W., & Neckers, L. M. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050817 · Cited by 478
Mimnaugh, E. G., Chavany, C., & Neckers, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22796 · Cited by 466
GELDANAMYCIN, A NEW ANTIBIOTIC
DEBOER, C., MEULMAN, P. A., WNUK, R. J., & PETERSON, D. H. (1970) · The Journal of Antibiotics · doi:10.7164/antibiotics.23.442 · Cited by 466
Schulte, T. W., Blagosklonny, M. V., Ingui, C., & Neckers, L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.24585 · Cited by 456
The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones.
Morimoto, R. I., Kline, M. P., Bimston, D. N., & Cotto, J. J. (1997) · PubMed · Cited by 435
Solit, D. B., Zheng, F. F., Drobnjak, M., Münster, P. N., Higgins, B., Verbel, D., Heller, G., Tong, W. P., Cordon‐Cardo, C., Agus, D. B., et al. (2002) · PubMed · Cited by 433
A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation
Yeh, K. C., & Kwan, K. C. (1978) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01066064 · Cited by 431
LAGRAN program for area and moments in pharmacokinetic analysis
Rocci, M. L., & Jusko, W. J. (1983) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(83)90082-x · Cited by 414
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
Schneider, C., Sepp-Lorenzino, L., Nimmesgern, E., Ouerfelli, O., Danishefsky, S., Rosen, N., & Hartl, F. U. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14536 · Cited by 405
Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.22.1940 · Cited by 350
The Hsp90 chaperone complex as a novel target for cancer therapy
Goetz, M. P., Toft, D. O., Ames, M. M., & Erlichman, C. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg316 · Cited by 334
Self-citationRole of the Cytosolic Chaperones Hsp70 and Hsp90 in Maturation of the Cardiac Potassium Channel hERG
Ficker, E., Dennis, A. T., Wang, L., & Brown, A. M. (2003) · Circulation Research · doi:10.1161/01.res.0000079028.31393.15 · Cited by 323
Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
Blagosklonny, M. V., Toretsky, J., Bohen, S., & Neckers, L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8379 · Cited by 314
Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D., & Rosen, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609973103 · Cited by 308
Solit, D. B., Basso, A. D., Olshen, A. B., Scher, H. I., & Rosen, N. X. (2003) · PubMed · Cited by 307
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
Smith-Jones, P. M., Solit, D. B., Akhurst, T., Afroze, F., Rosen, N., & Larson, S. M. (2004) · Nature Biotechnology · doi:10.1038/nbt968 · Cited by 304
Identification of a 60-kilodalton stress-related protein, p60, which interacts with hsp90 and hsp70.
Smith, D. F., Sullivan, W. P., Marion, T. N., Zaitsu, K., Madden, B., McCormick, D. J., & Toft, D. O. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.2.869 · Cited by 269
Self-citationSchulte, T. W., Blagosklonny, M. V., Romanova, L., Mushinski, J. F., Monia, B. P., Johnston, J. F., Nguyen, P., Trepel, J., & Neckers, L. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5839 · Cited by 269
Basso, A. D., Solit, D. B., Munster, P. N., & Rosen, N. (2002) · Oncogene · doi:10.1038/sj.onc.1205184 · Cited by 265
Grem, J. L., Morrison, G., Guo, X.-D., Agnew, E., Takimoto, C. H., Thomas, R., Szabo, E., Grochow, L., Grollman, F., Hamilton, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.085 · Cited by 242
Binding of p23 and hsp90 during assembly with the progesterone receptor.
Johnson, J. L., & Toft, D. O. (1995) · Molecular Endocrinology · doi:10.1210/mend.9.6.8592513 · Cited by 233
Self-citationCitri, A. (2002) · The EMBO Journal · doi:10.1093/emboj/21.10.2407 · Cited by 233
Uehara, Y., Hori, M., Takeuchi, T., & Umezawa, H. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.6.2198 · Cited by 233
Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N., & Sawyers, C. L. (2002) · Blood · doi:10.1182/blood-2002-05-1361 · Cited by 227
Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Sausville, E., Tomaszewski, J., & Ivy, P. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481831 · Cited by 225
Gelmon, K. A., Eisenhauer, E. A., Harris, A. L., Ratain, M. J., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1281 · Cited by 204
The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Whitesell, L., Bagatell, R., & Falsey, R. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481787 · Cited by 203
Schnur, R. C., Corman, M. L., Gallaschun, R. J., Cooper, B. A., Dee, M. F., Doty, J. L., Muzzi, M. L., Moyer, J. D., & DiOrio, C. I. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00019a010 · Cited by 199
Ramanathan, R. K., Trump, D. L., Eiseman, J. L., Belani, C. P., Agarwala, S. S., Zuhowski, E. G., Lan, J., Potter, D. M., Ivy, S. P., Ramalingam, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2322 · Cited by 194
Barent, R. L., Nair, S. C., Carr, D. C., Ruan, Y., Rimerman, R. A., Fulton, J., Zhang, Y., & Smith, D. F. (1998) · Molecular Endocrinology · doi:10.1210/mend.12.3.0075 · Cited by 190
Sepp-Lorenzino, L., Ma, Z., Lebwohl, D. E., Vinitsky, A., & Rosen, N. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16580 · Cited by 189
Münster, P. N., Basso, A., Solit, D., Norton, L., & Rosen, N. (2001) · PubMed · Cited by 173
Targeting Wide-Range Oncogenic Transformation via PU24FCl, a Specific Inhibitor of Tumor Hsp90
Vilenchik, M., Solit, D., Basso, A., Huezo, H., Lucas, B., He, H., Rosen, N., Spampinato, C., Modrich, P., & Chiosis, G. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.008 · Cited by 171
Banerji, U., Walton, M., Raynaud, F., Grimshaw, R., Kelland, L., Valenti, M., Judson, I., & Workman, P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0518 · Cited by 164
Hollingshead, M. G., Alley, M. C., Burger, A. M., Borgel, S. D., Pacula-Cox, C. M., Fiebig, H., & Sausville, E. A. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0939-2 · Cited by 153
Overview: Translating Hsp90 Biology into Hsp90 Drugs
Workman, P. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481868 · Cited by 139
Egorin, M. J., Rosen, D. M., Wolff, J., Callery, P. S., Musser, S. M., & Eiseman, J. L. (1998) · PubMed · Cited by 133
Egorin, M. J., Zuhowski, E. G., Rosen, D. M., Sentz, D. L., Covey, J. M., & Eiseman, J. L. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000242 · Cited by 133
Bagatell, R., Khan, O., Paine-Murrieta, G. D., Taylor, C. W., Akinaga, S., & Whitesell, L. J. (2001) · PubMed · Cited by 118
Gaedigk, A., Tyndale, R. F., Jurima‐Romet, M., Sellers, E. M., Grant, D. M., & Leeder, J. S. (1998) · Pharmacogenetics · doi:10.1097/00008571-199808000-00004 · Cited by 102
Lawson, B., Brewer, J. W., & Hendershot, L. M. (1998) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199802)174:2<170::aid-jcp4>3.0.co;2-l · Cited by 101
17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models
Burger, A. M., Fiebig, H., Stinson, S. F., & Sausville, E. A. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200404000-00011 · Cited by 89
de Candia, P., Solit, D. B., Giri, D. D., Brogi, E., Siegel, P. M., Olshen, A. B., Muller, W. J., Rosen, N. X., & Benezra, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2031337100 · Cited by 86
Nguyen, D. M., Lorang, D., Chen, G. A., Stewart, J. H., Tabibi, E., & Schrump, D. S. (2001) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(01)02787-4 · Cited by 78
Yang, J., Yang, J., Iannone, M. A., Shih, W. J., Lin, Y., & Hait, W. N. (2001) · PubMed · Cited by 70
Enmon, R. M., Yang, W.-H., Ballangrud, Å., Solit, D. B., Heller, G., Rosen, N. X., Scher, H. I., & Sgouros, G. (2003) · PubMed · Cited by 66
Identification of new biomarkers for clinical trials of Hsp90 inhibitors
Zhang, H., Chung, D., Yang, Y., Neely, L., Tsurumoto, S., Fan, J., Zhang, L., Biamonte, M. A., Brekken, J., Lundgren, K., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0537 · Cited by 61
Short circuiting stress protein expression via a tyrosine kinase inhibitor, herbimycin A
Hegde, R. S., Zuo, J., Voellmy, R. W., & Welch, W. J. (1995) · Journal of Cellular Physiology · doi:10.1002/jcp.1041650122 · Cited by 59
Xu, L., Eiseman, J. L., Egorin, M. J., & D’Argenio, D. Z. (2003) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1025542026488 · Cited by 57
Induction of hsp 72/73 by herbimycin A, an inhibitor of transformation by tyrosine kinase oncogenes
Murakami, Y., Uehara, Y., Yamamoto, C., Fukazawa, H., & Mizuno, S. (1991) · Experimental Cell Research · doi:10.1016/0014-4827(91)90382-5 · Cited by 46
Generation of DOTA-Conjugated Antibody Fragments for Radioimmunoimaging
Smith-Jones, P. M., & Solit, D. B. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)86012-9 · Cited by 10
Morimoto, R. I. (2002) · Encyclopedia of Molecular Biology · doi:10.1002/047120918x.emb0639 · Cited by 5
Cited by
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications
Ciocca, D. R., & Calderwood, S. K. (2005) · Cell Stress & Chaperones · doi:10.1379/csc-99r.1 · Cited by 1,404
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Nuclear lamin stiffness is a barrier to 3D migration, but softness can limit survival
Harada, T., Swift, J., Irianto, J., Shin, J.-W., Spinler, K. R., Athirasala, A., Diegmiller, R., Dingal, P. C. D. P., Ivanovska, I. L., & Discher, D. E. (2014) · Journal of Cell Biology · doi:10.1083/jcb.201308029 · Cited by 611
WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
Metadata
- Authors
- Goetz, M. P., Toft, D., Reid, J., Ames, M., Stensgard, B., Safgren, S., Adjei, A. A., Sloan, J., Atherton, P., Vasile, V., Salazaar, S., Adjei, A., Croghan, G., & Erlichman, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-02-20
- Volume
- 23
- Issue
- 6
- Pages
- 1078-1087
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2100611890
- Cited by
- 336
- References
- 68
- FWCI
- 15.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.